MedTrace Logo

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

NCT06003621 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2024-11-15

No results posted yet for this study

Summary

This phase II study will explore the effect of 2 monoclonal antibodies, tiragolumab and atezolizumab, in patients with locally advanced solid cancers which cannot be removed by surgery or have spread. Their cancers will have characteristics which may predict immune response to the study treatment. PD-L1 and TIGIT are immune receptors which can help cancers grow by evading the immune response and inhibiting the action of some immune cells. By blocking these receptors, tiragolumab and atezolizumab may work together to re-activate the body's anti-tumour immune response and kill cancer cells.

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

Tiragolumab

600mg IV every 21 days from Cycle 1 Day 1

BIOLOGICAL

Atezolizumab

1,200mg IV every 21 days from Cycle 2 Day 1

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • The George Institute for Global Health, Australia

    collaborator OTHER

  • Omico

    lead OTHER

Principal Investigators

  • David Thomas, PHD, FRACP · Omico; UNSW Sydney

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-15
Primary Completion
2026-05-01
Completion
2028-11-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06003621 on ClinicalTrials.gov